Equities

Valiant Laboratories Ltd

VALIANTLAB:NSI

Valiant Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)119.77
  • Today's Change-0.63 / -0.52%
  • Shares traded84.36k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 10:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments1,438361201
Total Receivables, Net4989051,124
Total Inventory100130158
Prepaid expenses------
Other current assets, total21910914
Total current assets2,2551,5061,497
Property, plant & equipment, net927488237
Goodwill, net------
Intangibles, net------
Long term investments341210
Note receivable - long term------
Other long term assets210124--
Total assets3,4272,1301,744
LIABILITIES
Accounts payable259473397
Accrued expenses------
Notes payable/short-term debt1400
Current portion long-term debt/capital leases2.311.7513
Other current liabilities, total153310
Total current liabilities291507420
Total long term debt751600594
Total debt767602607
Deferred income tax6.186.662.96
Minority interest------
Other liabilities, total101012
Total liabilities1,0581,1251,029
SHAREHOLDERS EQUITY
Common stock435326163
Additional paid-in capital------
Retained earnings (accumulated deficit)1,934679552
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity2,3691,005715
Total liabilities & shareholders' equity3,4272,1301,744
Total common shares outstanding433316
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.